Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Obesity01:24

Obesity

977
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
977
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

108
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
108
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

90
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
90
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

129
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
129
Stress Prevention and Stress Management Techniques IV01:26

Stress Prevention and Stress Management Techniques IV

147
Stress often leads to unhealthy habits like smoking, excessive drinking, and overeating, which offer short-term relief but ultimately increase long-term health risks. These behaviors create a cycle that temporarily lowers stress levels but can result in severe long-term health consequences. Breaking these habits is essential to reduce the risk of chronic diseases and improve overall well-being. Three primary changes that support better health include quitting smoking, reducing alcohol intake,...
147
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

704
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
704

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Identifying Predictors of Weight-Related Outcomes With Fixed-Dose, Extended-Release Naltrexone and Bupropion Among Treatment-Adherent Patients in Phase 3 COR Trials: A Treatment Target Analysis.

Obesity science & practice·2026
Same author

Tirzepatide for Obesity in Adults ≥ 65 Years: A Post Hoc Analysis of the SURMOUNT and SUMMIT Clinical Trials.

Diabetes, obesity & metabolism·2026
Same author

Semaglutide 25 mg Oral Versus Semaglutide 2.4 mg Injectable: An Indirect Treatment Comparison of Weight Loss Outcomes.

Diabetes, obesity & metabolism·2026
Same author

Oral Semaglutide 25 mg Versus Orforglipron 36 mg in Obesity: A Population-Adjusted Indirect Treatment Comparison.

Diabetes, obesity & metabolism·2026
Same author

Uncovering Gaps in Obesity Medicine Competencies: Insights from Ten U.S. Medical Schools.

Medical science educator·2026
Same author

Lifestyle Modification and Incretin-Based Therapy for Obesity.

JAMA·2026

Related Experiment Video

Updated: Dec 3, 2025

Multidisciplinary Approach to Obesity Management: A Case Report
05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

700

Overweight: The Overlooked Risk Factor.

Robert F Kushner1, Craig Primack2

  • 1Northwestern University Feinberg School of Medicine, Division of Endocrinology, Chicago, IL, USA.

The Journal of Family Practice
|October 26, 2020
PubMed
Summary
This summary is machine-generated.

This activity will equip family physicians to address overweight and obesity in the US. Learn about disease risks and effective non-procedural treatments for patient weight management.

More Related Videos

Assessment of Child Anthropometry in a Large Epidemiologic Study
09:36

Assessment of Child Anthropometry in a Large Epidemiologic Study

Published on: February 2, 2017

27.6K
A Chronic High-Intensity Interval Training and Diet-Induced Obesity Model to Maximize Exercise Effort and Induce Physiologic Changes in Rats
06:28

A Chronic High-Intensity Interval Training and Diet-Induced Obesity Model to Maximize Exercise Effort and Induce Physiologic Changes in Rats

Published on: April 28, 2023

1.2K

Related Experiment Videos

Last Updated: Dec 3, 2025

Multidisciplinary Approach to Obesity Management: A Case Report
05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

700
Assessment of Child Anthropometry in a Large Epidemiologic Study
09:36

Assessment of Child Anthropometry in a Large Epidemiologic Study

Published on: February 2, 2017

27.6K
A Chronic High-Intensity Interval Training and Diet-Induced Obesity Model to Maximize Exercise Effort and Induce Physiologic Changes in Rats
06:28

A Chronic High-Intensity Interval Training and Diet-Induced Obesity Model to Maximize Exercise Effort and Induce Physiologic Changes in Rats

Published on: April 28, 2023

1.2K

Area of Science:

  • Public Health
  • Clinical Medicine
  • Obesity Research

Background:

  • Overweight and obesity are significant public health issues in the United States.
  • These conditions are associated with substantial disease burden and impact patient quality of life.
  • Effective patient-physician communication is crucial for initiating weight management discussions.

Purpose of the Study:

  • To describe the epidemiology of overweight and obesity in the US.
  • To outline the disease burden linked to overweight status (body mass index 25-30 kg/m2).
  • To provide guidance on initiating weight management conversations with patients and differentiating non-procedural treatment options.

Main Methods:

  • Review of epidemiological data on overweight and obesity prevalence in the US.
  • Analysis of the health consequences and disease burden associated with overweight.
  • Evaluation of the safety and efficacy of two non-procedural device treatments for overweight individuals.

Main Results:

  • The activity will cover the latest statistics on overweight and obesity prevalence.
  • Key disease risks associated with a body mass index of 25-30 kg/m2 will be detailed.
  • Comparative analysis of two non-procedural interventions will be presented.

Conclusions:

  • Family physicians will gain a better understanding of overweight/obesity epidemiology and disease burden.
  • Physicians will be equipped with strategies to discuss weight management effectively.
  • Knowledge of non-procedural treatment options will be enhanced for improved patient care.